Skip to content
2000
Volume 22, Issue 1
  • ISSN: 1573-4048
  • E-ISSN: 1875-6581

Abstract

Introduction

Visfatin is a 52-kDa protein produced mainly by adipose tissue. It is one of the cytokines known as adipokines. There is a correlation between visfatin and female reproductive health, pregnancy complications, and gynecological cancers. This mini-review summarizes the existing knowledge of the role of visfatin in female reproduction and in various types of gynecological cancers.

Methods

We performed a literature search in the PubMed database up to December 2023. We reviewed the identified articles and included those that were relevant to our objective.

Results and Discussion

Visfatin has been implicated in the pathogenesis of polycystic ovary syndrome, while alterations in visfatin levels have been correlated with pregnancy complications, including gestational diabetes mellitus, acute pyelonephritis, preeclampsia, and reduced fetal growth. First trimester maternal visfatin levels are associated with infant weight. The role of visfatin has also been investigated in relation to steroidogenesis as well as breast, ovarian, and endometrial cancers. In those types of gynecological cancers, high visfatin levels were observed. Visfatin has also been detected in the follicular fluid, and it has been correlated with the number of retrieved oocytes in fertilization.

Conclusion

The results from published studies are contradictory because visfatin levels vary across conditions due to its complex mode of action. Visfatin could potentially serve as a prognostic biomarker in various reproductive conditions and as a therapeutic target in various types of gynecological cancers. Additional studies are needed to clarify visfatin’s role in female reproduction because its effects can vary depending on the tissue in which it is present.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cwhr/10.2174/0115734048343364250303044156
2025-03-06
2026-02-24

  • From This Site

    /content/journals/cwhr/10.2174/0115734048343364250303044156
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KoernerA. KratzschJ. KiessW. Adipocytokines: Leptin-the classical, resistin—the controversical, adiponectin—the promising, and more to come.Best Pract. Res. Clin. Endocrinol. Metab.200519452554610.1016/j.beem.2005.07.00816311215
     [Google Scholar]
  2. ShenC.J. TsaiE.M. LeeJ.N. ChenY.L. LeeC.H. ChanT.F. The concentrations of visfatin in the follicular fluids of women undergoing controlled ovarian stimulation are correlated to the number of oocytes retrieved.Fertil. Steril.20109361844185010.1016/j.fertnstert.2008.12.09019200966
     [Google Scholar]
  3. HugC. LodishH.F. Medicine. Visfatin: A new adipokine.Science2005307570836636710.1126/science.110693315604359
     [Google Scholar]
  4. SamalB. SunY. StearnsG. XieC. SuggsS. McNieceI. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.Mol. Cell. Biol.1994142143114378289818
     [Google Scholar]
  5. OgnjanovicS. Bryant-GreenwoodG.D. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes.Am. J. Obstet. Gynecol.200218741051105810.1067/mob.2002.12629512389004
     [Google Scholar]
  6. KendalC.E. Bryant-GreenwoodG.D. Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells.Placenta200728430531410.1016/j.placenta.2006.03.01116701870
     [Google Scholar]
  7. CuratC.A. WegnerV. SengenèsC. MiranvilleA. TonusC. BusseR. BouloumiéA. Macrophages in human visceral adipose tissue: Increased accumulation in obesity and a source of resistin and visfatin.Diabetologia200649474474710.1007/s00125‑006‑0173‑z16496121
     [Google Scholar]
  8. StępieńS. OlczykP. GolaJ. Komosińska-VassevK. Mielczarek-PalaczA. The role of selected adipocytokines in ovarian cancer and endometrial cancer.Cells2023128111810.3390/cells1208111837190027
     [Google Scholar]
  9. DakroubA. A NasserS. YounisN. BhaganiH. Al-DhaheriY. PintusG. EidA.A. El-YazbiA.F. EidA.H. Visfatin: A possible role in cardiovasculo-metabolic disorders.Cells2020911244410.3390/cells911244433182523
     [Google Scholar]
  10. LukT. MalamZ. MarshallJ.C. Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity.J. Leukoc. Biol.200883480481610.1189/jlb.080758118252866
     [Google Scholar]
  11. ArakiS. DobashiK. KuboK. KawagoeR. YamamotoY. KawadaY. AsayamaK. ShirahataA. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children.Obesity200816238438810.1038/oby.2007.5418239648
     [Google Scholar]
  12. Zahorska-MarkiewiczB. Olszanecka-GlinianowiczM. JanowskaJ. KocełakP. Semik-GrabarczykE. HoleckiM. DąbrowskiP. SkorupaA. Serum concentration of visfatin in obese women.Metabolism20075681131113410.1016/j.metabol.2007.04.00717618961
     [Google Scholar]
  13. HaiderD.G. SchallerG. KapiotisS. MaierC. LugerA. WolztM. The release of the adipocytokine visfatin is regulated by glucose and insulin.Diabetologia20064981909191410.1007/s00125‑006‑0303‑716736128
     [Google Scholar]
  14. ChenM.P. ChungF.M. ChangD.M. TsaiJ.C.R. HuangH.F. ShinS.J. LeeY.J. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.J. Clin. Endocrinol. Metab.200691129529910.1210/jc.2005‑147516234302
     [Google Scholar]
  15. TilgH. MoschenA.R. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity.Nat. Rev. Immunol.200661077278310.1038/nri193716998510
     [Google Scholar]
  16. DahlT.B. YndestadA. SkjellandM. ØieE. DahlA. MichelsenA. DamåsJ.K. TunheimS.H. UelandT. SmithC. BendzB. TonstadS. GullestadL. FrølandS.S. Krohg-SørensenK. RussellD. AukrustP. HalvorsenB. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization.Circulation2007115897298010.1161/CIRCULATIONAHA.106.66589317283255
     [Google Scholar]
  17. IsmaielA. LeucutaD.C. PopaS.L. DumitrascuD.L. Serum visfatin levels in nonalcoholic fatty liver disease and liver fibrosis: Systematic review and meta-analysis.J. Clin. Med.20211014302910.3390/jcm1014302934300193
     [Google Scholar]
  18. HanD.F. LiY. XuH.Y. LiR.H. ZhaoD. An update on the emerging role of visfatin in the pathogenesis of osteoarthritis and pharmacological intervention.Evid. Based Complement. Alternat. Med.202020201830357010.1155/2020/830357032831881
     [Google Scholar]
  19. ChanT.F. ChenY.L. LeeC.H. ChouF.H. WuL.C. JongS.B. TsaiE.M. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.J. Soc. Gynecol. Investig.200613536436710.1016/j.jsgi.2006.04.00716814166
     [Google Scholar]
  20. HaiderD.G. HandisuryaA. StorkaA. VojtassakovaE. LugerA. PaciniG. TuraA. WolztM. Kautzky-WillerA. Visfatin response to glucose is reduced in women with gestational diabetes mellitus.Diabetes Care20073071889189110.2337/dc07‑001317416788
     [Google Scholar]
  21. AkturkM. AltinovaA.E. MertI. BuyukkagniciU. SarginA. ArslanM. DanismanN. Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.J. Endocrinol. Invest.200831761061310.1007/BF0334561118787378
     [Google Scholar]
  22. RezvanN. Hosseinzadeh-AttarM.J. MasoudkabirF. MoiniA. JananiL. MazaheriounM. Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy.Arch. Gynecol. Obstet.201228551257126210.1007/s00404‑011‑2156‑722167446
     [Google Scholar]
  23. LewandowskiK.C. StojanovicN. PressM. TuckS.M. SzoslandK. BienkiewiczM. VatishM. LewinskiA. PrelevicG.M. RandevaH.S. Elevated serum levels of visfatin in gestational diabetes: A comparative study across various degrees of glucose tolerance.Diabetologia20075051033103710.1007/s00125‑007‑0610‑717334748
     [Google Scholar]
  24. KrzyzanowskaK. KruglugerW. MittermayerF. RahmanR. HaiderD. ShnawaN. SchernthanerG. Increased visfatin concentrations in women with gestational diabetes mellitus.Clin. Sci.2006110560560910.1042/CS2005036316489932
     [Google Scholar]
  25. MaY. ChengY. WangJ. ChengH. ZhouS. LiX. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes.Diabetes Res. Clin. Pract.2010901606510.1016/j.diabres.2010.06.01020621376
     [Google Scholar]
  26. CoskunA. OzkayaM. KiranG. KilincM. ArikanD.C. Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus.J. Matern. Fetal Neonatal Med.20102391014101810.3109/1476705090355142620059442
     [Google Scholar]
  27. Mazaki-ToviS. VaisbuchE. RomeroR. KusanovicJ.P. ChaiworapongsaT. KimS.K. Nhan-ChangC.L. GomezR. YoonB.H. YeoL. MittalP. OggeG. GonzalezJ.M. HassanS.S. Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis.Am. J. Reprod. Immunol.201063325226210.1111/j.1600‑0897.2009.00804.x20085562
     [Google Scholar]
  28. FasshauerM. WaldeyerT. SeegerJ. SchreyS. EbertT. KratzschJ. LossnerU. BluherM. StumvollM. FaberR. StepanH. Serum levels of the adipokine visfatin are increased in pre‐eclampsia.Clin. Endocrinol.2008691697310.1111/j.1365‑2265.2007.03147.x18034779
     [Google Scholar]
  29. AdaliE. YildizhanR. KolusariA. KurdogluM. BugdayciG. SahinH.G. KamaciM. Increased visfatin and leptin in pregnancies complicated by pre-eclampsia.J. Matern. Fetal Neonatal Med.2009221087387910.1080/1476705090299462219488934
     [Google Scholar]
  30. ZorbaE. VavilisD. VenetisC.A. ZournatziV. KellartzisD. TarlatzisB.C. Visfatin serum levels are increased in women with preeclampsia: A case-control study.J. Matern. Fetal Neonatal Med.20122591668167310.3109/14767058.2012.65727522272940
     [Google Scholar]
  31. HuW. WangZ. WangH. HuangH. DongM. Serum visfatin levels in late pregnancy and pre‐eclampsia.Acta Obstet. Gynecol. Scand.200887441341810.1080/0001634080197601218382866
     [Google Scholar]
  32. KimS.C. ParkM.J. JooB.S. JooJ.K. SuhD.S. LeeK.S. Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia.J. Obstet. Gynaecol. Res.201238466567310.1111/j.1447‑0756.2011.01773.x22380724
     [Google Scholar]
  33. Malamitsi-PuchnerA. BrianaD.D. BoutsikouM. KouskouniE. HassiakosD. GourgiotisD. Perinatal circulating visfatin levels in intrauterine growth restriction.Pediatrics20071196e1314e131810.1542/peds.2006‑258917502346
     [Google Scholar]
  34. ValsamakisG. PapatheodorouD.C. MargeliA. BakoulasV. KapantaisE. PapassotiriouI. CreatsasG. KumarS. MastorakosG. First trimester maternal BMI is a positive predictor of cord blood c-peptide levels while maternal visfatin levels is a negative predictor of birth weight.Hormones2014131879410.1007/BF0340132424722131
     [Google Scholar]
  35. GoodarziM.O. DumesicD.A. ChazenbalkG. AzzizR. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis.Nat. Rev. Endocrinol.20117421923110.1038/nrendo.2010.21721263450
     [Google Scholar]
  36. ChenX. JiaX. QiaoJ. GuanY. KangJ. Adipokines in reproductive function: A link between obesity and polycystic ovary syndrome.J. Mol. Endocrinol.2013502R21R3710.1530/JME‑12‑024723335807
     [Google Scholar]
  37. TayC.T. GarradR. MousaA. BahriM. JohamA. TeedeH. Polycystic ovary syndrome (PCOS): International collaboration to translate evidence and guide future research.J. Endocrinol.20232573e22023236946556
     [Google Scholar]
  38. BozdagG. MumusogluS. ZenginD. KarabulutE. YildizB.O. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis.Hum. Reprod.201631122841285510.1093/humrep/dew21827664216
     [Google Scholar]
  39. MatalliotakisI. KourtisA. KoukouraO. PanidisD. Polycystic ovary syndrome: Etiology and pathogenesis.Arch. Gynecol. Obstet.2006274418719710.1007/s00404‑006‑0171‑x16685527
     [Google Scholar]
  40. EhrmannD.A. Polycystic ovary syndrome.N. Engl. J. Med.2005352121223123610.1056/NEJMra04153615788499
     [Google Scholar]
  41. LegatoM.J. Gender-specific aspects of obesity.Int. J. Fertil. Womens Med.19974231841979222803
     [Google Scholar]
  42. BjörntorpP. Abdominal obesity and the metabolic syndrome.Ann. Med.199224646546810.3109/078538992091669971485940
     [Google Scholar]
  43. TanB.K. ChenJ. DigbyJ.E. KeayS.D. KennedyC.R. RandevaH.S. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: Parallel increase in plasma visfatin.J. Clin. Endocrinol. Metab.200691125022502810.1210/jc.2006‑093617003086
     [Google Scholar]
  44. ChanT.F. ChenY.L. ChenH.H. LeeC.H. JongS.B. TsaiE.M. Increased plasma visfatin concentrations in women with polycystic ovary syndrome.Fertil. Steril.200788240140510.1016/j.fertnstert.2006.11.12017335820
     [Google Scholar]
  45. KowalskaI. StraczkowskiM. NikolajukA. AdamskaA. Karczewska-KupczewskaM. OtziomekE. WolczynskiS. GorskaM. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.Hum. Reprod.20072271824182910.1093/humrep/dem11817582143
     [Google Scholar]
  46. PanidisD. FarmakiotisD. RoussoD. KatsikisI. DelkosD. PioukaA. GerouS. Diamanti-KandarakisE. Plasma visfatin levels in normal weight women with polycystic ovary syndrome.Eur. J. Intern. Med.200819640641210.1016/j.ejim.2007.05.01418848173
     [Google Scholar]
  47. CarminaE. BucchieriS. MansuetoP. RiniG. FerinM. LoboR.A. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome.Fertil. Steril.2009914Suppl.1332133510.1016/j.fertnstert.2008.03.00718455165
     [Google Scholar]
  48. OzkayaM. CakalE. UstunY. Engin-UstunY. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.Fertil. Steril.201093388088410.1016/j.fertnstert.2008.10.05819111298
     [Google Scholar]
  49. PlatiE. KouskouniE. Malamitsi-PuchnerA. BoutsikouM. KaparosG. BakaS. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation.Fertil. Steril.20109441451145610.1016/j.fertnstert.2009.04.05519523615
     [Google Scholar]
  50. SeowK.M. HwangJ.L. WangP.H. HoL.T. JuanC.C. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome.Hum. Reprod.201126102869287310.1093/humrep/der26721840905
     [Google Scholar]
  51. TsoumaI. KouskouniE. DemeridouS. BoutsikouM. HassiakosD. ChasiakouA. HassiakouS. GennimataV. BakaS. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: Influence of adipocytokines levels.In Vivo201428593593925189910
     [Google Scholar]
  52. SpanosN. TziomalosK. MacutD. KoiouE. KandarakiE.A. DelkosD. TsourdiE. PanidisD. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: Cross-sectional correlations and the effects of weight loss.Obes. Facts20125449550410.1159/00034157922854419
     [Google Scholar]
  53. SethiJ.K. Vidal-PuigA. Visfatin: The missing link between intra-abdominal obesity and diabetes?Trends Mol. Med.200511834434710.1016/j.molmed.2005.06.01016005682
     [Google Scholar]
  54. SunY. WuZ. WeiL. LiuC. ZhuS. TangS. High-visfatin levels in women with polycystic ovary syndrome: Evidence from a meta-analysis.Gynecol. Endocrinol.2015311080881410.3109/09513590.2015.105614026422683
     [Google Scholar]
  55. GüdücüN. İşçiH. GörmüşU. YiğiterA.B. DünderI. Serum visfatin levels in women with polycystic ovary syndrome.Gynecol. Endocrinol.201228861962310.3109/09513590.2011.65074922313145
     [Google Scholar]
  56. Olszanecka-GlinianowiczM. MadejP. ZdunD. Bożentowicz-WikarekM. SikoraJ. ChudekJ. SkałbaP. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?Eur. J. Obstet. Gynecol. Reprod. Biol.20121621556110.1016/j.ejogrb.2012.01.02622397743
     [Google Scholar]
  57. PanidisD. FarmakiotisD. RoussoD. KatsikisI. KourtisA. Diamanti-KandarakisE. Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary syndrome.Fertil. Steril.200584253854010.1016/j.fertnstert.2005.02.01716084906
     [Google Scholar]
  58. Diamanti-KandarakisE. BartzisM.I. ZapantiE.D. SpinaG.G. FilandraF.A. TsianateliT.C. BergieleA.T. KouliC.R. Polymorphism T→C (−34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome.Fertil. Steril.199971343143510.1016/S0015‑0282(98)00512‑310065777
     [Google Scholar]
  59. NestlerJ. PowersL.P. MattD.W. SteingoldK.A. PlymateS.R. RittmasterR.S. CloreJ.N. BlackardW.G. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.J. Clin. Endocrinol. Metab.1991721838910.1210/jcem‑72‑1‑831898744
     [Google Scholar]
  60. ChangY.C. ChangT.J. LeeW.J. ChuangL.M. The relationship of visfatin/pre–B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.Metabolism2010591939910.1016/j.metabol.2009.07.01119765775
     [Google Scholar]
  61. SteinerC.A. JanezA. JensterleM. ReisingerK. ForstT. PfütznerA. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.J. Diabetes Sci. Technol.20071221121710.1177/19322968070010021219888409
     [Google Scholar]
  62. ChenJ. HuL. LingY. XuY. YuX. MaL. ShouM. Risk correlation analysis between polycystic ovary syndrome (PCOS) and serum visfatin levels in middle-aged women: Systematic review and meta-analysis.Discov. Med.20233517516817710.24976/Discov.Med.202335175.1737105926
     [Google Scholar]
  63. BannigidaD.M. NayakS.B. R, V. Serum visfatin and adiponectin – Markers in women with polycystic ovarian syndrome.Arch. Physiol. Biochem.2020126428328610.1080/13813455.2018.151898730318936
     [Google Scholar]
  64. AliA.I. NoriW. Correlation of serum visfatin level in non-obese women with polycystic ovary syndrome and matched control.Reprod. Sci.202229113285329310.1007/s43032‑022‑00986‑z35687303
     [Google Scholar]
  65. DuleyL. The global impact of pre-eclampsia and eclampsia.Semin. Perinatol.200933313013710.1053/j.semperi.2009.02.01019464502
     [Google Scholar]
  66. SteegersE.A.P. von DadelszenP. DuvekotJ.J. PijnenborgR. Pre-eclampsia.Lancet2010376974163164410.1016/S0140‑6736(10)60279‑620598363
     [Google Scholar]
  67. LyallF. The human placental bed revisited.Placenta2002238-955556210.1053/plac.2002.085012361674
     [Google Scholar]
  68. KimY.M. BujoldE. ChaiworapongsaT. GomezR. YoonB.H. ThalerH.T. RotmenschS. RomeroR. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes.Am. J. Obstet. Gynecol.200318941063106910.1067/S0002‑9378(03)00838‑X14586356
     [Google Scholar]
  69. IvesC.W. SinkeyR. RajapreyarI. TitaA.T.N. OparilS. Preeclampsia-pathophysiology and clinical presentations.J. Am. Coll. Cardiol.202076141690170210.1016/j.jacc.2020.08.01433004135
     [Google Scholar]
  70. HaugenF. RanheimT. HarsemN.K. LipsE. StaffA.C. DrevonC.A. Increased plasma levels of adipokines in preeclampsia: Relationship to placenta and adipose tissue gene expression.Am. J. Physiol. Endocrinol. Metab.20062902E326E33310.1152/ajpendo.00020.200516144822
     [Google Scholar]
  71. CortelazziD. CorbettaS. RonzoniS. PelleF. MarconiA. CozziV. CetinI. CortelazziR. Beck-PeccozP. SpadaA. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies.Clin. Endocrinol.200766344745310.1111/j.1365‑2265.2007.02761.x17302882
     [Google Scholar]
  72. Mazaki-ToviS. RomeroR. KimS.K. VaisbuchE. KusanovicJ.P. ErezO. ChaiworapongsaT. GotschF. MittalP. Nhan-ChangC.L. ThanN.G. GomezR. NienJ.K. EdwinS.S. PacoraP. YeoL. HassanS.S. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?J. Matern. Fetal Neonatal Med.201023885786810.3109/1476705090330101719900033
     [Google Scholar]
  73. Mazaki-ToviS. VaisbuchE. RomeroR. KusanovicJ.P. ChaiworapongsaT. KimS.K. Nhan-ChangC.L. GomezR. Alpay SavasanZ. MadanI. YoonB.H. YeoL. MittalP. OggeG. GonzalezJ.M. HassanS.S. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate.J. Matern. Fetal Neonatal Med.201023101119112810.3109/1476705090357219020121389
     [Google Scholar]
  74. BawahA.T. YeboahF.A. NangaS. AliduH. NgalaR.A. Serum adipocytokines and adiposity as predictive indices of preeclampsia.Clin. Hypertens.20202611910.1186/s40885‑020‑00152‑033014422
     [Google Scholar]
  75. Amiri-DashatanN. KoushkiM. HosseiniH. KhodabandehlooH. FathiM. DoustimotlaghA.H. Rezaei-TaviraniM. Association between circulating visfatin and pre-eclampsia: A systematic review and meta-analysis.J. Matern. Fetal Neonatal Med.202235132606261810.1080/14767058.2020.178958132635792
     [Google Scholar]
  76. Malamitsi-PuchnerA. BrianaD.D. GourgiotisD. BoutsikouM. BakaS. HassiakosD. Blood visfatin concentrations in normal full‐term pregnancies.Acta Paediatr.200796452652910.1111/j.1651‑2227.2007.00231.x17391471
     [Google Scholar]
  77. BrianaD.D. Malamitsi-PuchnerA. The role of adipocytokines in fetal growth.Ann. N. Y. Acad. Sci.201012051828710.1111/j.1749‑6632.2010.05650.x20840257
     [Google Scholar]
  78. GluckmanP.D. HansonM.A. PinalC. The developmental origins of adult disease.Matern. Child Nutr.20051313014110.1111/j.1740‑8709.2005.00020.x16881892
     [Google Scholar]
  79. KiessW. PetzoldS. TöpferM. GartenA. BlüherS. KapellenT. KörnerA. KratzschJ. Adipocytes and adipose tissue.Best Pract. Res. Clin. Endocrinol. Metab.200822113515310.1016/j.beem.2007.10.00218279785
     [Google Scholar]
  80. BrianaD.D. BoutsikouM. GourgiotisD. KontaraL. BakaS. IacovidouN. HassiakosD. Malamitsi-PuchnerA. Role of visfatin, insulin-like growth factor-I and insulin in fetal growth.J. Perinat. Med.200735432632910.1515/JPM.2007.07117511597
     [Google Scholar]
  81. NasriK. MehrabiM. BayaniM. Almasi-HashianiA. Maternal saliva visfatin level in term and preterm labor: A case control study.PLoS One2023187e028878610.1371/journal.pone.028878637459321
     [Google Scholar]
  82. HillJ.B. SheffieldJ.S. McIntireD.D. Wendel JrG.D. Acute pyelonephritis in pregnancy.Obstet. Gynecol.20051051182310.1097/01.AOG.0000149154.96285.a015625136
     [Google Scholar]
  83. FoxmanB. KlemstineK.L. BrownP.D. Acute pyelonephritis in US hospitals in 1997: Hospitalization and in-hospital mortality.Ann. Epidemiol.200313214415010.1016/S1047‑2797(02)00272‑712559674
     [Google Scholar]
  84. GilstrapL.C.III CunninghamF.G. WhalleyP.J. Acute pyelonephritis in pregnancy: An anterospective study.Obstet. Gynecol.19815744094137243084
     [Google Scholar]
  85. GurmanG. SchlaefferF. KopernicG. Adult respiratory distress syndrome as a complication of acute pyelonephritis during pregnancy.Eur. J. Obstet. Gynecol. Reprod. Biol.1990361-2758010.1016/0028‑2243(90)90052‑32194868
     [Google Scholar]
  86. ColeD.E. TaylorT.L. McCulloughD.M. ShoffC.T. DerdakS. Acute respiratory distress syndrome in pregnancy.Crit. Care Med.20053310Suppl.S269S27810.1097/01.CCM.0000182478.14181.DA16215347
     [Google Scholar]
  87. MabieW. BartonJ.R. SibaiB. Septic shock in pregnancy.Obstet. Gynecol.199790455356110.1016/S0029‑7844(97)00352‑99380315
     [Google Scholar]
  88. SheffieldJ.S. Sepsis and septic shock in pregnancy.Crit. Care Clin.200420465166010.1016/j.ccc.2004.05.01215388194[viii.
     [Google Scholar]
  89. KusanovicJ.P. RomeroR. EspinozaJ. GotschF. EdwinS. ChaiworapongsaT. MittalP. SotoE. ErezO. Mazaki-ToviS. ThanN.G. FrielL.A. YoonB.H. MazorM. HassanS.S. Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis.J. Matern. Fetal Neonatal Med.2007201180381110.1080/1476705070149285117853184
     [Google Scholar]
  90. ChaiworapongsaT. RomeroR. GotschF. KusanovicJ.P. MittalP. KimS.K. ErezO. VaisbuchE. Mazaki-ToviS. KimC.J. DongZ. YeoL. HassanS.S. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma.J. Matern. Fetal Neonatal Med.201023216717810.3109/1476705090306737820213923
     [Google Scholar]
  91. GotschF. RomeroR. EspinozaJ. KusanovicJ.P. Mazaki-ToviS. ErezO. ThanN.G. EdwinS. MazorM. YoonB.H. HassanS.S. Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy.J. Matern. Fetal Neonatal Med.2007201073574410.1080/1476705070151165017763275
     [Google Scholar]
  92. NienJ.K. RomeroR. HoppensteadtD. ErezO. EspinozaJ. SotoE. KusanovicJ.P. GotschF. KimC.J. MittalP. FareedJ. SantolayaJ. ChaiworapongsaT. EdwinS. PinelesB. HassanS. Pyelonephritis during pregnancy: A cause for an acquired deficiency of protein Z.J. Matern. Fetal Neonatal Med.200821962963710.1080/1476705080221465918828054
     [Google Scholar]
  93. SotoE. RichaniK. RomeroR. EspinozaJ. ChaiworapongsaT. NienJ.K. EdwinS. KimY.M. HongJ.S. GoncalvesL. MazorM. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy.J. Matern. Fetal Neonatal Med.200517424725210.1080/1476705050007280516147833
     [Google Scholar]
  94. Mazaki-ToviS. RomeroR. KusanovicJ.P. ErezO. GotschF. MittalP. ThanN.G. Nhan-ChangC.L. HamillN. VaisbuchE. ChaiworapongsaT. EdwinS.S. NienJ.K. GomezR. EspinozaJ. Kendal-WrightC. HassanS.S. Bryant-GreenwoodG. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: An association with subclinical intrauterine infection in preterm parturition.J. Perinat. Med.200836648549610.1515/JPM.2008.08418598235
     [Google Scholar]
  95. MetzgerB.E. CoustanD.R. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus.Diabetes Care199821Suppl. 2B161B1679704245
     [Google Scholar]
  96. DabeleaD. Snell-BergeonJ.K. HartsfieldC.L. BischoffK.J. HammanR.F. McDuffieR.S. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser permanente of colorado GDM screening program.Diabetes Care200528357958410.2337/diacare.28.3.57915735191
     [Google Scholar]
  97. TsiotraP.C. HalvatsiotisP. PatsourasK. MaratouE. SalamalekisG. RaptisS.A. DimitriadisG. BoutatiE. Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus.Peptides201810115716610.1016/j.peptides.2018.01.00529337272
     [Google Scholar]
  98. BawahA.T. SeiniM.M. Abaka-YawasonA. AliduH. NangaS. Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus.Lipids Health Dis.201918122110.1186/s12944‑019‑1169‑231836012
     [Google Scholar]
  99. Souvannavong-VilivongX. SitticharoonC. KlinjampaR. KeadkraichaiwatI. SripongC. ChatreeS. SririwichitchaiR. LertbunnaphongT. Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM.Acta Diabetol.201956101121113110.1007/s00592‑019‑01355‑031076892
     [Google Scholar]
  100. FerreiraA.F.A. RezendeJ.C. VaikousiE. AkolekarR. NicolaidesK.H. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.Clin. Chem.201157460961310.1373/clinchem.2010.15980621325104
     [Google Scholar]
  101. TelejkoB. KuzmickiM. ZonenbergA. SzamatowiczJ. Wawrusiewicz-KurylonekN. NikolajukA. KretowskiA. GorskaM. Visfatin in gestational diabetes: Serum level and mRNA expression in fat and placental tissue.Diabetes Res. Clin. Pract.2009841687510.1016/j.diabres.2008.12.01719185944
     [Google Scholar]
  102. MorganS.A. BringolfJ.B. SeidelE.R. Visfatin expression is elevated in normal human pregnancy.Peptides20082981382138910.1016/j.peptides.2008.04.01018524416
     [Google Scholar]
  103. ZhaoxiaL. YingW. DanqingC. Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus.Diabetes Res. Clin. Pract.2012963e76e7910.1016/j.diabres.2012.02.02022446095
     [Google Scholar]
  104. LeeY.C. YangY.H. SuJ.H. ChangH.L. HouM.F. YuanS.S.F. High visfatin expression in breast cancer tissue is associated with poor survival.Cancer Epidemiol. Biomarkers Prev.20112091892190110.1158/1055‑9965.EPI‑11‑039921784959
     [Google Scholar]
  105. BegumP. RichardsonC.E. CarmichaelA.R. Obesity in post menopausal women with a family history of breast cancer: Prevalence and risk awareness.Int. Semin. Surg. Oncol.200961110.1186/1477‑7800‑6‑119133122
     [Google Scholar]
  106. HouW. XuY. YuT. ZhangL. ZhangW. FuC. SunY. WuQ. ChenL. Adipocytokines and breast cancer risk.Chin. Med. J.2007120181592159610.1097/00029330‑200709020‑0000917908478
     [Google Scholar]
  107. BrownA. RaynorP. LeeM. Young mothers who choose to breast feed: The importance of being part of a supportive breast-feeding community.Midwifery2011271535910.1016/j.midw.2009.09.00419896254
     [Google Scholar]
  108. Koike FolgueiraM.A.A. CarraroD.M. BrentaniH. da Costa PatrãoD.F. BarbosaE.M. NettoM.M. CaldeiraJ.R.F. KatayamaM.L.H. SoaresF.A. OliveiraC.T. ReisL.F.L. KaianoJ.H.L. CamargoL.P. VêncioR.Z.N. SnitcovskyI.M.L. MakdissiF.B.A. da Silva e Silva, P.J.; Góes, J.C.G.S.; Brentani, M.M. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.Clin. Cancer Res.200511207434744310.1158/1078‑0432.CCR‑04‑054816243817
     [Google Scholar]
  109. BaeS.K. KimS.R. KimJ.G. KimJ.Y. KooT.H. JangH.O. YunI. YooM.A. BaeM.K. Hypoxic induction of human visfatin gene is directly mediated by hypoxia‐inducible factor‐1.FEBS Lett.2006580174105411310.1016/j.febslet.2006.06.05216828081
     [Google Scholar]
  110. YonezawaT. HagaS. KobayashiY. TakahashiT. ObaraY. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway.FEBS Lett.200658028-296635664310.1016/j.febslet.2006.11.01417123517
     [Google Scholar]
  111. WangY.Y. HungA.C. LoS. YuanS.S.F. Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.Cancer Lett.202149822923910.1016/j.canlet.2020.10.04533152400
     [Google Scholar]
  112. GhaneialvarH. ShiriS. KenarkoohiA. Fallah VastaniZ. AhmadiA. KhorshidiA. KhoozR. Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta‐analysis.Health Sci. Rep.202256e89510.1002/hsr2.89536415563
     [Google Scholar]
  113. ShackelfordR.E. BuiM.M. CoppolaD. HakamA. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.Int. J. Clin. Exp. Pathol.20103552252720606733
     [Google Scholar]
  114. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  115. MakkerV. MacKayH. Ray-CoquardI. LevineD.A. WestinS.N. AokiD. OakninA. Endometrial cancer.Nat. Rev. Dis. Primers2021718810.1038/s41572‑021‑00324‑834887451
     [Google Scholar]
  116. TerzicM. AimagambetovaG. KunzJ. BapayevaG. AitbayevaB. TerzicS. LaganàA.S. Molecular basis of endometriosis and endometrial cancer: Current knowledge and future perspectives.Int. J. Mol. Sci.20212217927410.3390/ijms2217927434502183
     [Google Scholar]
  117. YenT.T. WangT.L. FaderA.N. ShihI.M. GaillardS. Molecular classification and emerging targeted therapy in endometrial cancer.Int. J. Gynecol. Pathol.2020391263510.1097/PGP.000000000000058530741844
     [Google Scholar]
  118. TrojanoG. OlivieriC. TinelliR. DamianiG.R. PellegrinoA. CicinelliE. Conservative treatment in early stage endometrial cancer: A review.Acta Biomed.201990440541031910163
     [Google Scholar]
  119. DingS. MaduC.O. LuY. The impact of hormonal imbalances associated with obesity on the incidence of endometrial cancer in postmenopausal women.J. Cancer202011185456546510.7150/jca.4758032742493
     [Google Scholar]
  120. WangY. GaoC. ZhangY. GaoJ. TengF. TianW. YangW. YanY. XueF. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.Gynecol. Oncol.2016143116817810.1016/j.ygyno.2016.07.10927473926
     [Google Scholar]
  121. Cymbaluk-PłoskaA. Chudecka-GłazA. Pius-SadowskaE. Sompolska-RzechułaA. MachalińskiB. MenkiszakJ. Circulating serum level of visfatin in patients with endometrial cancer.BioMed Res. Int.2018201811910.1155/2018/857617929516012
     [Google Scholar]
  122. LuhnP. DallalC.M. WeissJ.M. BlackA. HuangW.Y. LaceyJ.V.Jr HayesR.B. StanczykF.Z. WentzensenN. BrintonL.A. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.Cancer Epidemiol. Biomarkers Prev.20132271304131210.1158/1055‑9965.EPI‑13‑025823696194
     [Google Scholar]
  123. IlhanT.T. KebapcilarA. YilmazS.A. IlhanT. KerimogluO.S. PekinA.T. AkyurekF. UnluA. CelikC. Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis.Asian Pac. J. Cancer Prev.201516114503450810.7314/APJCP.2015.16.11.450326107194
     [Google Scholar]
  124. RayI. MeiraL.B. MichaelA. EllisP.E. Adipocytokines and disease progression in endometrial cancer: A systematic review.Cancer Metastasis Rev.202241121124210.1007/s10555‑021‑10002‑634951691
     [Google Scholar]
  125. MichalczykK. NiklasN. RychlickaM. Cymbaluk-PłoskaA. The influence of biologically active substances secreted by the adipose tissue on endometrial cancer.Diagnostics202111349410.3390/diagnostics1103049433799622
     [Google Scholar]
  126. ReverchonM. CornuauM. CloixL. RaméC. GuerifF. RoyèreD. DupontJ. Visfatin is expressed in human granulosa cells: Regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.Mol. Hum. Reprod.201319531332610.1093/molehr/gat00223315983
     [Google Scholar]
  127. ZhouJ. SeidelE.R. Estrogens induce visfatin expression in 3T3-L1 cells.Peptides201031227127410.1016/j.peptides.2009.12.00420004694
     [Google Scholar]
  128. TsoumaI. KouskouniE. DemeridouS. BoutsikouM. HassiakosD. ChasiakouA. HassiakouS. BakaS. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation.Gynecol. Endocrinol.201430751651910.3109/09513590.2014.89689624576225
     [Google Scholar]
  129. FiedlerK. EzcurraD. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): The need for individualized not standardized treatment.Reprod. Biol. Endocrinol.20121013210.1186/1477‑7827‑10‑3222531097
     [Google Scholar]
/content/journals/cwhr/10.2174/0115734048343364250303044156
Loading
The Role of Visfatin in Female Reproduction and Various Types of Gynecological Cancers
Curr Womens Health Rev. 22, E15734048343364 (2026); https://doi.org/10.2174/0115734048343364250303044156
/content/journals/cwhr/10.2174/0115734048343364250303044156
/content/journals/cwhr/10.2174/0115734048343364250303044156
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Adipokines; adipose tissue; insulin resistance; obesity; PCOS; preeclampsia; reproduction; visfatin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test